Humanizing implants

Clinical Needs

The Fibrotic Reaction

Passive and active implantable devices are subjected to high rates of severe fibrotic reaction.

No effective strategy is clinically available to prevent this fibrotic reaction.

  • 1 Intraocular Lens (IOL)
  • 2 Dental Implants
  • 3 Pacemakers & Defibrillators
  • 4 Breast & Aesthetic Implants
  • 5 Silicone Gastric Bands
  • 6 Insulin Implantable Pumps
  • 7 Orthopedic Implants

This fibrotic reaction, if untreated, presents significantly negative consequences for the patient.


Humanizing Implants

MYcoat™ addresses a medical problem. Once an implant is inserted into the body, the body's immune response calls for fybroblasts near the implant to activate, turning into myofibroblasts. These myofibroblasts, in turn, attach to the implant in a process known as "docking". Over time, this "docking" causes deterioration of the implant's function due to capsular contraction.

We developed MYcoat™ to specifically address this issue. MYcoat™ mimicks human tissue and sets up the architecture around the implant in order to effectively prevent the activation of fibroblasts, thus significantly reducing and, in some cases, preventing "docking". This, in turn, helps to prevent implant capsular contraction, helping the patient to reduce exposure to experiencing pain, infections, increased medical costs and loss of function of the implant device.

We developed MYcoat™ to humanize implants.

Technology Results

In-Vitro Results

During the first experiments In-Vitro, the labseed team demonstrated:

  • reproducibility in recreating the coating without macroscopic changes in the coated material,
  • prevention of myofibroblast development and proliferation (10-fold decrease compared to control condition in presence and absence of stimulatory cytokines),
  • creation of a covalent binding between a silicone surface and the MYcoat™, the strongest binding possible.

More details in:
Majd, H., et al., Biomaterials 54 (2015), pp. 136-147

Read more


In-Vivo Results

One year post implantation, MYcoat™ silicone implants did not exhibit the formation of a clinically relevant capsule, while standard controls induced the formation of a thick capsule made of scar tissue. The labseed MYcoat™ results show a stable reduction of capsular contraction once the process of acute inflammation around the implant is extinguished. MYcoat™ modulates the first interactions between the implant and host body, guiding the process toward a non-fibrotic type of response.

More details in
Majd, H., et al., Biomaterials 54 (2015), pp. 136-147

Read more


Labseed is a spin-off from the École Polytechnique Fédérale de Lausanne (EPFL), in Switzerland, and we became incorporated in 2009.

We developed MYcoat,™ a unique product consisting of a treatment surface which reduces the level of fibrotic reaction and rejection of implantable medical devices.

We are supported by the Swiss Commission for Technology and Innovation (CTI), Discovery Project N° 10447: Smart Coating for Implantable Medical Devices.


Our Business Model

Bringing MYcoat™ to market
Labseed acquires a generic or normal implant from implant manufacturers.
Labseed coats implant with appropriate MYcoat™ technology, then selects the packaging and applies sterilization to preserve implant's function and quality.
Labseed sells coated implant to manufacturers and distributors with its MYcoat™ trademark.

MYcoat™ Development Process

Generic implant acquisition
Apply MYcoat™ coating
Selection of specific packaging
Sterilization of coated implants
Regulatory tests and certification
CE Mark / 510k
Access to market
Clinical Trials

Our Partners

Our Business Partner

Institut de Traumatologie et d’Orthopédie du Léman Suisse


Our Academic Partners

Laboratory of Biomechanical Orthopedics (LBO)
Microsystems Laboratory 4 (LMIS 4)


Laboratory of Tissue Repair and Regeneration


Service de Chirurgie Plastique et de La Main



EPFL News Mediacom

January 30, 2012

A technology developed by labseed, an EPFL spin-off, could prevent most breast implant rejections.

More than a quarter of all breast implants must be removed within four years, because neighboring tissues develop...


Reflexe Magazine

December 2010

Labseed is developing a technology that will make implants more biocompatible.

"It was the ideal solution for bringing our technology to market." As soon as he was convinced of his research's commercial potential...


Le Temps

February 23, 2010

La mise en place d'un implant est perçue comme un corps étranger. Petit à petit, une réaction fribrotique a lieu. Une cicatrice, ou plus exactement une capsule fibrotique, va se former et limiter parfois la fonctionnalité de l'implant. Une nouvelle...


Venture 2010 - Switzerland

Recent Developments

European Patent Office - Patent Guaranteed

Patent name: Coated medical device and method of coating a medical device to reduce fibrosis and capsule formation.

Patent Number EP2331152. The patent was been granted on 19.05.2017 and published on 21.06.2017 

Priority number and date: EP20080163816 (05.09.2008)

Designated contracting states: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR.


Fill out the following form to send us a message